基本药物统一定价可行性分析  

Research on Essential Medicines Unified Pricing

作　　者：常峰[1] 李思函[1] 

机构地区：[1]中国药科大学医药产业发展研究中心,江苏南京211198

出　　处：《中国药物评价》2013年第2期117-120,128,共5页Chinese Journal of Drug Evaluation

基　　金：<基本药物招标采购过程中药品质量评估研究>;项目来源:国家食品与药品监督管理局;<廉价药品统一定价机制研究>;项目来源:江苏省物价局;<新版GMP对药品价格的影响>;项目来源:广东医药价格协会

摘　　要：目的:探索基本药物统一定价机制的可行性,为完善我国基本药物定价政策提供建议。方法:分析我国基本药物价格现状,从政策层面分析基本药物统一定价趋势,建立基本药物统一价格模型。结果与结论:为保障基本药物制度的顺利实施,应坚持成本加成定价法为基本药物进行统一定价,并建立配套机制保证其实施效果,保障基本药物的可及性。Objective：To explore the feasibility of essential medicines unified pricing mechanism, and put forward advices for perfecting our country essential medicines pricing policies. Methods：Analysis of current essential drug prices in our country, and establish essential medicines unified pricing model through policy analysis of essential drugs unified pricing trends. Results and Conclusion： In order to guar- antee the smooth implementation of the system for essential medicines, we should adhere to the cost-plus pricing method for essential medi- cines unified pricing, and establish a mechanism to ensure its effect of implementation, and ensure the accessibility of essential medicines.

关 键 词：基本药物 定价机制 统一定价 

分 类 号：R95[医药卫生—药学]